Literature DB >> 20436718

Hematopoietic stem cell transplantation after posttransplant lymphoproliferative disorder.

Min Joo Kim1, Inho Kim, Hyun-Mi Bae, Kyungsuk Seo, Namjun Park, Sung-Soo Yoon, Seonyang Park, Byoung Kook Kim.   

Abstract

A 16-yr-old girl received liver transplantation for fulminant hepatitis. Aplastic anemia developed, and she received hematopoietic stem cell transplantation (HSCT). Eleven months after liver transplantation, abdominal lymph node enlargement and colon ulcers were observed, and colon biopsy showed posttransplant lymphoproliferative disorder (PTLD). Immunosuppression reduction was attempted, but it produced no therapeutic effect. Fourteen months after liver transplantation, she received a second HSCT due to engraftment failure, and PTLD resolved completely. The second HSCT can serve as cellular therapy for PTLD.

Entities:  

Keywords:  Liver Transplantation; Posttransplant Lymphoproliferative Disorder, Hematopoietic Stem Cell Transplantation

Mesh：

Year:  2010        PMID： 20436718      PMCID： PMC2858841          DOI： 10.3346/jkms.2010.25.5.781

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN： 1011-8934            Impact factor:   2.153


  20 in total

Review 1.  Epstein-Barr virus and lymphoproliferative disorders after transplantation.

Authors: 
Journal:  Am J Transplant       Date:  2004-11       Impact factor: 8.086

2.  Lymphomas and lymphoproliferative lesions developing under cyclosporin therapy.

Authors:  T Beveridge; P Krupp; C McKibbin
Journal:  Lancet       Date:  1984-04-07       Impact factor: 79.321

3.  Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment.

Authors:  Valter Duro Garcia; José Luz Bonamigo Filho; Jorge Neumann; Laura Fogliatto; Anna Maria Geiger; Clotilde Druck Garcia; Vivianne Barros; Elizete Keitel; Antonio Eduardo Bittar; Auri Ferrera des Santos; Sergio Roithmann
Journal:  Transpl Int       Date:  2003-02-13       Impact factor: 3.782

Review 4.  Classification of Epstein-Barr virus-associated posttransplant lymphoproliferative diseases: implications for understanding their pathogenesis and developing rational treatment strategies.

Authors:  D W Hanto
Journal:  Annu Rev Med       Date:  1995       Impact factor: 13.739

5.  Impaired recovery of Epstein-Barr virus (EBV)--specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease.

Authors:  Pauline Meij; Joost W J van Esser; Hubert G M Niesters; Debbie van Baarle; Frank Miedema; Neil Blake; Alan B Rickinson; Ingrid Leiner; Eric Pamer; Bob Lowenberg; Jan J Cornelissen; Jan W Gratama
Journal:  Blood       Date:  2003-02-06       Impact factor: 22.113

6.  Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation.

Authors:  E B Papadopoulos; M Ladanyi; D Emanuel; S Mackinnon; F Boulad; M H Carabasi; H Castro-Malaspina; B H Childs; A P Gillio; T N Small
Journal:  N Engl J Med       Date:  1994-04-28       Impact factor: 91.245

7.  An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation.

Authors:  K L Cox; L S Lawrence-Miyasaki; R Garcia-Kennedy; E T Lennette; O M Martinez; S M Krams; W E Berquist; S K So; C O Esquivel
Journal:  Transplantation       Date:  1995-02-27       Impact factor: 4.939

8.  The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation.

Authors:  K G Lucas; T N Small; G Heller; B Dupont; R J O'Reilly
Journal:  Blood       Date:  1996-03-15       Impact factor: 22.113

9.  Pretransplantation assessment of the risk of lymphoproliferative disorder.

Authors:  R C Walker; W F Marshall; J G Strickler; R H Wiesner; J A Velosa; T M Habermann; C G McGregor; C V Paya
Journal:  Clin Infect Dis       Date:  1995-05       Impact factor: 9.079

Review 10.  Posttransplant malignancy.

Authors:  Jennifer Trofe; Thomas M Beebe; Joseph F Buell; Michael J Hanaway; M Roy First; Rita R Alloway; Thomas G Gross; E Steve Woodle
Journal:  Prog Transplant       Date:  2004-09       Impact factor: 1.065
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.